Could a COVID-19 vaccine – or vaccines – be approved before the November election? That’s the bold prediction being made by Jefferies – and if the major biotechnology investing research firm is correct, it would be a big deal for investors. The author of today’s article, however, argues that, “Ironically, early vaccine approvals probably won’t mean much for investors who have already enjoyed good runs in vaccine developers” – and points to other parts of the market that could be the real winners. For more, CLICK HERE.